Ionis Pharmaceuticals

Impact: Ionis Pharmaceuticals entered into a license agreement with Recordati for zilganersen outside the U.S., retaining U.S. commercial rights and receiving an upfront payment of $30 million, milestone payments, and royalties. This deal strengthens its position in neurology and rare diseases.

Impact: Ionis's stock plunged 23.9%, losing over $3.3 billion in market cap; it is the primary target of multiple securities investigations.

Impact: Ionis Pharmaceuticals co-developed bepirovirsen, and the positive trial results and potential approval could lead to substantial financial gains and increased market presence for the company.

Impact: Ionis partnered with Biogen on diranersen, an antisense oligonucleotide. Positive trial results enhance Ionis's platform value and pipeline prospects.

Impact: Ionis Pharmaceuticals, a mid-sized drugmaker, expressed disinterest in the United States — Medicaid pilot program due to its business model and limited upside, highlighting the challenges in getting smaller companies to participate.

Impact: Ionis Pharmaceuticals discovered diranersen and licensed it to Biogen in 2019, making it a beneficiary of any future success of the drug.

Impact: Ionis Pharmaceuticals is the partner for Wainua, which failed in a heart disease trial earlier this year, contributing to the series of setbacks for AstraZeneca.

Impact: Ionis Pharmaceuticals is mentioned as the former company of n-Lorem's founder, but is not directly involved in this collaboration.